Form D · Biotechnology
Outpace Bio, Inc.
Seattle, WA · CIK 0002031531
Offering snapshot reported Aug 1, 2024 · SEC filing
- Reported sold
- $56M Offering amount: $144M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 17, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 1, 2024 | Initial | $55,999,992 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-520350
Source: Form D, filed Aug 1, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vasudev Bailey | Director |
| Scott Boyken | Director, Executive, Promoter |
| Aaron Foster | Executive |
| Bahija Jallal | Director |
| Marc Lajoie | Director, Executive, Promoter |
| Charity Scripture | Executive |
| Jake Simson | Director |
| Eric Soller | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
700 Dexter Ave N, Suite 300
Seattle, WA, 98109
Seattle, WA, 98109